Article Text

Download PDFPDF
Cutaneous leishmaniasis associated with TNF-α blockers: a case report
  1. Pelayo Nieto Gómez1,
  2. Inmaculada Casas Hidalgo1,
  3. María de la Paz Casas Hidalgo2,
  4. Raquel Álvarez Sánchez1,
  5. Alejandro Rodríguez Delgado1,
  6. Jose Cabeza-Barrera3
  1. 1 Farmacia Hospitalaria, Hospital Universitario San Cecilio, Granada, Spain
  2. 2 Servicio de Microbiología y Parasitología, Hospital Universitario San Cecilio, Granada, Spain
  3. 3 Pharmacy, Hospital Universitaro San Cecilio, Granada, Spain
  1. Correspondence to Pelayo Nieto Gómez, Farmacia Hospitalaria, Hospital Universitario San Cecilio, Granada 18012, Spain; pnietog90{at}


Leishmaniasis is a chronic protozoan disease that is found in diverse geographical areas of the world. Leishmania spp. are endemic in the Mediterranean coasts of southern Europe. Tumour necrosis factor alpha (TNF-α) plays an important role in the defence of the host against infection by Leishmania spp. In this case report we describe Leishmania infection caused by a monoclonal antibody against TNF-α: infliximab. A 51-year-old patient with psoriatic arthritis treated with infliximab, 5 mg/kg every 6 weeks as immunomodulatory treatment and methotrexate 10 mg weekly as a conventional disease-modifying antirheumatic drug, visited his otorhinolaryngologist owing to a lesion in his left nostril. The lesion was diagnosed as cutaneous leishmaniasis so treatment with infliximab was suspended. The patient was then treated with liposomal amphotericin B and showed a total recovery of the lesion; liposomal amphotericin B was maintained at 5 mg/kg monthly.

  • leishmaniasis
  • immunosuppression
  • infliximab
  • anti-tnf
  • psoriatic arthritis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.